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Three decades of clinical research on repetitive transcranial magnetic stimulation (rTMS)
has yielded one clear treatment indication in psychiatry for major depression disorder
(MDD). Although the clinical response equals the standard treatment algorithms, the
effect sizes on the beneficial outcome remain rather modest. Over the last couple
of years, to improve the efficacy in resistant depression, two new avenues have
been developed: personalization and intensifying rTMS treatment. For the latter, we
retrospectively compared accelerated high-frequency rTMS (arTMS) with accelerated
intermittent theta burst stimulation (aiTBS) in the refractory depressed state. Although
the clinical efficacy was not significantly different between both protocols, our
observations substantiate the potential of the accelerated stimulation to shorten the
treatment duration from the depressed state to the response state. Any time gain from
the depressed state to the recovered state is in the patients’ interest.
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INTRODUCTION
Three decades of clinical repetitive transcranial magnetic stimulation (rTMS) research has resulted
in only one clear indication for the treatment of (moderate) medication-resistant major depression
in the field of psychiatry, specifically when stimulating the left dorsolateral prefrontal cortex
(DLPFC) (Lefaucheur et al., 2014). Despite the many parameter adjustments tested over the past
years, the rTMS outcome rates remain rather modest (Brunoni et al., 2017), meaning that only
3 or 4 out of 10 patients undergoing rTMS are going to respond, but will not be necessarily
remitted. Importantly, like electroconvulsive therapy (ECT), another widely used neurostimulation
application for treating patients with major depressive disorder (MDD), the rTMS must also be
considered as an acute treatment option with relatively fast but no definitive long-term clinical
improvement. Electroconvulsive therapy is considered to be one of our most potent treatment
modalities in the acute phase of depression, yielding “unchallenged” response rates when compared
with the classic pharmacological and current rTMS treatment algorithms (Baeken et al., 2013).
After approximately 10 sessions of unilateral or bilateral (bifrontal/bitemporal) ECT, 80–90% of
the treated depression patients will clinically respond (Kennedy and Giacobbe, 2007). Of note,
when including the treatment-resistant depression (TRD) patients, the response rates tend to be
a bit lower, which is around 50–70% (Rush and Siefert, 2009).
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Over the last couple of years, to optimize the rTMS treatment
efficacy, the individualization of rTMS parameters (Padberg et al.,
2017) and intense rTMS paradigms are under investigation
(Holtzheimer et al., 2010). For the first approach, to accurately
target the stimulation area, individual anatomical data are
included (Fitzgerald et al., 2009), individual brain connectivity
patterns are selected (Fox et al., 2012), or depression “biotypes”
based on the brain network analysis are targeted (Drysdale
et al., 2017). The second approach, accelerated rTMS (arTMS)
treatment, applies multiple daily sessions, reducing the total time
period of stimulation by just over a couple of days. This is
in contrast to the classical daily single rTMS sessions, which
usually spread over 2–4 weeks and sometimes even longer
(Holtzheimer et al., 2010; Baeken et al., 2015). It is of interest
to note that when applied to the left DLPFC, no significant
differences in remission or response rates or reductions in
depression severity scores were observed between the accelerated
and the classical daily rTMS treatments (Fitzgerald et al.,
2018).
Newer stimulation parameters, which deliver pulses even on
a shorter amount of time, compare the excitatory stimulation
protocols of high-frequency rTMS (HF-rTMS) and intermittent
theta-burst stimulation (iTBS), when applied to the dorsomedial
prefrontal cortex (dmPFC). Bakker et al. (2015) did not find
any differences in clinical outcome between these two protocols.
Recently, in a large, randomized, non-inferiority trial with TRD
patients, Blumberger et al. (2018) also reported no differences
in the clinical outcome between HF-rTMS and iTBS treatments,
when applied to the left DLPFC.
From a clinical perspective, it would be highly interesting
if we could apply “intensified” rTMS treatment algorithms,
resulting not only in fast clinical improvement but also in
reaching the response and remission rates as observed with
ECT. As mostly refractory depression patients are selected
for ECT (besides psychotic and catatonic depression), we
retrospectively compared our aHF-rTMS with accelerated iTBS
(aiTBS) treatments in this research (Baeken et al., 2013; Duprat
et al., 2016), by only selecting stage III TRD patients. We expected
that in this refractory MDD sample, response and remission
rates would not be significantly different between the patients
receiving aHF-rTMS or aiTBS treatments. We also evaluated on
the assumption that arTMS treatment would reach comparable
remission rates [remission defined as a final score on the 17-item
Hamilton Depression Rating Scale score ≤ 7 (HDRS: Hamilton,
1967)], as observed with ECT.
MATERIALS AND METHODS
From the original samples of our former aHF-rTMS and aiTBS
accelerated paradigms comprising of patients with varying stages
of treatment resistance (Baeken et al., 2013; Duprat et al., 2016),
we have included only rTMS naïve unipolar stage III TRD
patients in this research (Rush et al., 2003), with a mean duration
of their current depression episode of 6.26 years (sd = 8.29),
confirming only to the refractory MDD (Ward and Irazoqui,
2010). As ECT non-response is a poor predictor of clinical
response to rTMS, stage V TRD patients were not included
(George and Post, 2011).
A total of 28 stage III TRD patients remained, with 14 in each
group. According to the criteria of Rush et al. (2003), all patients
had a minimum of two unsuccessful psychopharmaceutical
treatment trials with a selective serotonin reuptake inhibitor
(SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI),
and one failed clinical trial with a tricyclic antidepressant (TCA).
After a washout period, all patients were noted as antidepressant-
free, at least 2 weeks before entering the studies. Exclusion criteria
were current or history of epilepsy, neurosurgical interventions,
metal objects in the brain, having a pacemaker, having had ECT,
alcohol dependence, and suicide attempts within 6 months before
the start of the study. Bipolar and psychotic depressed patients
were also excluded. Following standard practice, clinical response
was defined as a 50% reduction of the baseline 17-item HDRS
score (Hamilton, 1967) by certified psychiatrists not related to the
studies.
In both accelerated sham-controlled crossover protocols, all
refractory MDD patients were randomized to receive either active
or sham stimulation (20 sessions in total, 5 sessions per day for 4
days) at 110% of the resting motor threshold. In the following
week, the order was reversed. For aHF-rTMS (20 Hz) treatment,
patients received 40 trains of 1.9 s duration, separated by an inter-
train interval of 12 s (1560 pulses per session) (Baeken et al.,
2013). For the accelerated iTBS treatment trial, patients received
40 trains (1620 pulses per session) in 54 triplet bursts with a train
duration of 2 s and a cycling of 8 s period (Duprat et al., 2016).
In both studies, we targeted exactly the same region of the left
DLPFC under MRI guidance.
RESULTS
No significant differences on depression severity scores were
observed between the two arTMS protocols. The 2 (Time; before
vs. after treatment)× 2 (Group; aiTBS vs. HF-rTMS)× 2 (Order;
first active then sham vs. first sham then active) analysis of
variance (ANOVA) with individual HDRS scores as dependent
variables showed a significant main effect of Time F(2,48) = 15.98,
p < 0.01 but not of Group F(1,24) = 0.02, p = 0.88 or Order
F(1,24) = 0.22, p = 0.64. The two-way interactions between Group
and Order, Time and Order, and Time and Group were all not
significant (p’s > 0.05). Also, the three-way interaction between
Time, Order, and Group was not significant F(2,48) = 0.20,
p = 0.82 (Figure 1). Separately mixed ANOVAs, separated for 1–2
weeks also showed non-significant results. Pearson X2 showed no
group differences in the remission rates [X2(1) = 1.12, p = 0.28].
Also, no significant demographic differences were observed. See
Table 1.
DISCUSSION
Aligned with the classical daily HF-rTMS/iTBS clinical outcome
findings (Bakker et al., 2015; Blumberger et al., 2018),
our observations with the accelerated aHF-rTMS/aiTBS
treatment protocols suggest similar clinical effects.
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FIGURE 1 | Graphical representation of the HDRS scores (mean and standard deviations) at baseline (T1), after 1-week (T2), and after 2-weeks of stimulation (T3) for
aHF-rTMS and aiTBS treatment separately.
TABLE 1 | Demographic and outcome variables.
All aHF-rTMS aiTBS p-values
Number of patients 28 14 14 −
Gender (F/M) 14:14 8:6 6:8 0.45
Age 48.37 (11.74) 47.86 (13.58) 48.86 (10.05) 0.83
Response T3 (yes/no) 10 7 3 0.12
Remission T3 (yes/no) 4 3 1 0.28
Duration current depressive episode (years) 6.26 (8.29) 7.89 (8.03) 4.62 (8.51) 0.31
Order (R>S) 9:19 6:8 3:11 0.23
Benzodiazepine intake (number) 14 9 6 0.26
Benzodiazepine intake (mg/day) 10.11 (11.74) 11.71 (13.25) 8.50 (10.27) 0.48
rMT (%) 59.86 (6.27) 60.00 (4.98) 59.71 (7.54) 0.91
HDRS T1 24.07 (6.10) 24.86 (6.42) 23.29 (5.89) 0.51
HDRS T2 19.36 (7.21) 19.07 (7.95) 19.64 (6.69) 0.84
HDRS T3 15.82 (8.34) 15.43 (9.39) 16.21 (7.48) 0.81
HDRS T4 − − 15.71 (8.23) −
Response T4 (yes/no) − − 5 −
Remission T4 (yes/no) − − 3 −
For these sham-controlled crossover studies, the 17-item HDRS was assessed at three time points. At baseline (T1), 3 days after the first round of (active or sham)
accelerated 20 stimulation sessions (T2), and 3 days after the second round of 20 stimulation sessions (reversed order) (T3), the response is defined as at least a 50%
reduction of the baseline HDRS score at T3. Remission is defined as having a final HDRS score of ≤ 7. T4 indicates the time of assessment for 2 weeks after the last
measurement, after T3. These data were only collected for the aiTBS study.
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Although no significant differences between the two accelerated
protocols were detected, 35% of the patients in the refractory
depressed state responded, which was in line with the classical
rTMS treatment response outcome for depression patients
(Brunoni et al., 2017). For the remission rates, the 14% remission
outcome seems rather low but is still in the range of results
observed with the direct classical daily rTMS treatment, which
is around 18.6% (Berlim et al., 2014). Of note, although the
remission rates remained unchanged for 2 weeks after the acute
treatment phase for aHF-rTMS (personal communication), the
remission rates doubled after 2 weeks for aiTBS stimulation
(Duprat et al., 2016), suggesting that the response and remission
rates may be delayed for aiTBS. This is not contradictive
to the neurophysiological effects, which are assumed to be
induced by iTBS (Chung et al., 2015). In the current stage III
study, as a result of adding the two remitters 2 weeks after
having ended the aiTBS stimulation protocol (see Table 1),
the remission outcome for both accelerated protocols was
21%.
It also seems that in the refractory depressed state, the
response and remission rates are somewhat lower when including
the less resistant depressed patients for the arTMS paradigms
(Baeken et al., 2013: aHF-rTMS response: 35%, remission: 35%;
Duprat et al., 2016: aiTBS response: 38%, remission: 30%),
daily left DLPFC stimulation (Blumberger et al., 2018: HF-rTMS
response: 47%, remission: 27%; iTBS response: 49%, remission:
32%), and daily dmPFC stimulation (Bakker et al., 2015: HF-
rTMS response: 50.6% remission: 38.5 %; iTBS response: 48.5%,
remission: 27.9%). However, given the limited number of large,
placebo-controlled arTMS trials, this assumption is merely
speculative at this point. Indeed, before taking firm conclusions
for this retrospective stage III study, we clearly lacked sufficient
power. To even find a small effect size of f = 0.10 in an ANOVA,
for a post hoc calculation of repeated measures of ANOVA with a
total sample of 28 patients, the power to find a group difference
is 0.19, which is rather low (calculated with G-Power 3.1.9.2.).
To properly address the question of whether arTMS paradigms
could be as successful as ECT in refractory depression, large,
multicenter, randomized, non-inferiority, placebo-controlled
clinical trials will be necessary to compare arTMS with ECT in
such samples. The absence of clinical differential effects between
the sham and the active accelerated treatment suggests some
form of placebo effect. Placebo responses in depressed patients
undergoing rTMS have been reported earlier (Berman et al.,
2000), and hopes and beliefs for a new treatment approach,
after numerous failed pharmacological and psychotherapeutic
interventions (Mommaerts and Devroey, 2012), may add to
a placebo effect. On the other hand, a recent meta-analysis
showed that the placebo effect may be a component of rTMS
therapeutic response (Razza et al., 2018). Nevertheless, the
standard contrasting to the accelerated left DLPFC and HF-
rTMS treatment (Fitzgerald et al., 2018: standard response:
29.8%, remission: 17.5%; accelerated: 20.3%, remission: 11.9%)
did not show any significant differences between the protocols,
suggesting that standard daily and arTMS have similar clinical
outcome rates in MDD.
Altogether, regardless of brain target, frequency, or coils, the
response and remission rates do not seem to be that different
between the rTMS paradigms. This also implies that within
current safety parameters and stimulation guidelines, we may
have reached a ceiling effect to treat depression, although with
acceptable clinical results (compared to pharmacotherapy), but
not with the outcomes of ECT. New types of coils, such as the
H1 coil, as well as magnetic seizure therapy (MST) are used
to improve the clinical outcome with some potential for higher
remission rates (Harel et al., 2014; Cretaz et al., 2015), however,
not with that magnitude to challenge the current ECT outcome
rates. Individualization of the rTMS parameters has rightfully
gained attention (Padberg et al., 2017) as Drysdale et al. (2017)
were able to apply the machine learning algorithms (resting
state fMRI), identifying the four biotypes of depression and
increasing the prediction of response after dmPFC stimulation
to 93.6%, when combining the connectivity and clinical features.
Whether such scientific approaches will positively affect the
future response and remission rates remains to be determined.
CONCLUSION
Applying the current rTMS parameters for depression patients
seems to yield similar response and remission rates, regardless
of the stimulation protocols used. So the major impact of the
arTMS protocols is the important gain of time. Instead of daily
application for 4–6 weeks, similar results are to be expected when
concentrating all sessions over a couple of days. From a patient as
well as from a medical view, the restriction on the duration of the
depressive episode may be a major motivation to consider arTMS.
However, any rTMS treatment protocol has to be considered
as an acute treatment, and the improvement and maintenance
of clinical effects should remain as a priority in the field of
neurostimulation, further pursuing clinical outcomes challenging
the successes of ECT in refractory depression, especially for
remission.
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